BPC-157 Human Trials: What Is Underway in 2026

BPC-157 is one of the most discussed peptides in wellness and sports circles, yet for years almost everything known about it came from animal studies. That is starting to change. This article explains what the first registered human trials are testing, what they cannot tell us yet, and how to read claims about BPC-157 in the meantime. It is educational and is not medical advice.

Key takeaways

• BPC-157 is a synthetic peptide fragment studied for tissue repair. Nearly all published evidence comes from animal and laboratory work.
• Much of that animal research comes from a single research group, which is one reason independent confirmation matters.
• At least two human trials are registered: one in hamstring strain and one, not yet recruiting, in rotator cuff repair.
• No results from either trial are expected before 2027.
• BPC-157 is not an FDA-approved drug.

What is BPC-157?

BPC-157 is a short chain of 15 amino acids (a pentadecapeptide) modeled on a fragment of a protein found in human gastric juice. In rodents it has been linked to faster healing of tendon, muscle, gut and nerve tissue, and researchers have proposed effects on blood vessel growth and inflammation. In several of these experiments, injured animals that received the peptide healed faster than untreated animals. Those findings are interesting, but animal results frequently do not carry over to people.

Where the animal evidence comes from

A large share of the published BPC-157 papers originate from one research group in Zagreb, Croatia, and its collaborators. That does not make the results wrong, but science gains confidence when different, independent laboratories reproduce a finding. For BPC-157, independent replication has been limited, and that is a central caveat when reading headlines about the peptide.

Why human data has been so scarce

Human trials are expensive, and BPC-157 is a molecule that is hard to patent in a way that rewards a large sponsor. As a result, the human record has been limited to very small studies and case reports. Reviews of the field have repeatedly pointed to this gap between enthusiasm and controlled evidence.

Oral or injected: an open question

One reason BPC-157 gets attention is the claim that it resists breakdown in stomach acid, since it is derived from a gastric protein, and so might work when swallowed. That idea comes mainly from the same body of animal research. Whether oral BPC-157 reaches tissues in meaningful amounts in people, and whether it does anything there, has not been shown in controlled human trials. The two registered human trials described below use injections, not capsules.

Trial 1: hamstring strain (NCT07437547)

According to registry summaries, a Phase 2, randomized, double-blind, placebo-controlled trial sponsored by Hudson Biotech is testing BPC-157 in acute Grade II hamstring strain, which is a partial muscle tear. Reports describe about 120 participants, recruitment starting in February 2026 and primary completion around February 2027. Public summaries do not clearly state the dose or the main outcome measure.

Trial 2: rotator cuff repair (NCT07803250)

A University of Arkansas pilot, registered in September 2026 and not yet recruiting, plans to test BPC-157 after arthroscopic rotator cuff repair. Participants are described as adults with an MRI-confirmed full-thickness tear under 2.5 cm.

• Design: randomized and masked, comparing daily BPC-157 injections with saline for 90 days after surgery.
• Main measure: shoulder strength, with MRI tendon healing, range of motion, patient-reported outcomes and blood markers of collagen turnover and inflammation as additional measures.
• Timing: a planned start in January 2027 and primary completion around August 2027.
• Open details: the planned enrollment is reported as both 20 and 30, and no dose has been published.

Both trials are summarized here from secondary reporting. The registry entries on ClinicalTrials.gov are the authoritative source, so check them for current details.

What these trials can and cannot answer

• They can show whether BPC-157 improves recovery on specific measures in a specific injury, compared with placebo.
• They are small and short, so they say little about rare side effects or long-term safety.
• Results from a hamstring or shoulder study do not automatically apply to other conditions, such as chronic nerve pain, or to people with health issues the trials exclude.

Why personal success stories are not evidence

Social media is full of posts from people who say BPC-157 relieved long-standing pain. These accounts are real experiences for the people sharing them, but they cannot tell us whether the peptide caused the change. Pain fluctuates, injuries often improve on their own, people change other habits at the same time, and expectation alone can reduce pain. A placebo-controlled trial exists to separate those factors from a genuine treatment effect. Until such trials report, a personal story should be treated as a reason to run a study, not as proof.

How to read BPC-157 claims in the meantime

• Animal results are not human results. A rat finding is a hypothesis for people, not proof.
• Check who produced the evidence. Findings repeated by independent labs carry more weight than those from a single group.
• Testimonials are not trials. Without a placebo group, natural healing is easy to mistake for a treatment effect.
• Be wary of confident dosing advice. No effective or safe human dose has been established in published controlled trials.
• Source quality matters. Products sold for "research use only" can vary in purity and sterility. See our guide to peptide safety and quality and our explainer on research-use-only versus prescription peptides.
• Rules are moving. Compounding policy for peptides has been changing in 2026. See our overview of how FDA compounding rules work for peptides, and confirm BPC-157's current status with a pharmacist or regulatory attorney.

Frequently asked questions

Has BPC-157 been tested in humans?

Only in very small studies so far. Controlled trials are now registered, but results are not expected before 2027.

Is BPC-157 FDA-approved?

No. It is not approved for any medical use in the US.

Does BPC-157 work when swallowed?

That has been proposed based on animal research and its origin in gastric juice, but it has not been shown in controlled human trials.

Can BPC-157 heal nerve damage?

Animal studies have reported effects on nerve injury, but there is no controlled human evidence that it treats nerve damage or chronic nerve pain.

When will we know if it works?

The hamstring trial is listed as completing around early 2027 and the rotator cuff pilot around mid to late 2027. Even then, one small trial will not settle the question.

Is BPC-157 safe?

Long-term human safety is not established. Anyone considering any peptide should speak with a licensed clinician first.

Sources

• ClinicalTrials.gov: NCT07437547, Phase 2 hamstring strain trial
• ClinicalTrials.gov: NCT07803250, rotator cuff repair pilot
• The Peptide Catalog: BPC-157 rotator cuff trial (secondary summary)
• Peptiq: first controlled human trial recruiting (secondary summary)

This article is for educational purposes only and is not medical advice. It has not been evaluated by the FDA and is not intended to diagnose, treat, cure or prevent any disease. Consult a licensed healthcare provider before starting any treatment.